Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...
Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...
Hosted on MSN3d
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds ExpectationsInsulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...
Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...
TipRanks on MSN1d
Insulet’s Financial Challenges: Navigating Pandemic Risks and Cybersecurity ThreatsInsulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category. Insulet faces significant business and financial risks ...
Canaccord raised the firm’s price target on Insulet (PODD) to $324 from $304 and keeps a Buy rating on the shares. The firm said they reported ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...
Zacks.com on MSN3d
Insulet (PODD) Q4 Earnings and Revenues Top EstimatesInsulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Good afternoon ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode. Later we will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback